

In the Claims:

The following is merely a listing of the presently-pending claims. No claim amendments are being made at this time.

1-20. (canceled)

21. (previously presented) A composition comprising the isolated polypeptide of claim 37 and a pharmaceutically-acceptable carrier.

22-36. (canceled)

37. (previously presented) An isolated mammalian REMODEL polypeptide, wherein the amino acid sequence of said REMODEL consists of SEQ ID NO:4.

38. (withdrawn) The isolated mammalian REMODEL polypeptide of claim 37, wherein the amino acid sequence of said REMODEL polypeptide consists of SEQ ID NO:2.

39. (canceled)

40. (withdrawn) The isolated mammalian REMODEL polypeptide of claim 37, wherein the amino acid sequence of said REMODEL polypeptide consists of SEQ ID NO:5.

41-42. (canceled)

43. (previously presented) An isolated chimeric polypeptide comprising a tag polypeptide covalently linked to a mammalian REMODEL polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:4, wherein said tag polypeptide is selected from the group consisting of a green fluorescent protein tag polypeptide, an influenza virus hemagglutinin tag polypeptide, a myc tag polypeptide, a glutathione-S-transferase tag polypeptide, a myc-pyruvate kinase tag polypeptide, a His6 tag polypeptide, a FLAG tag polypeptide, and a maltose binding protein tag polypeptide.

44. (withdrawn) A recombinant cell comprising the isolated polypeptide of claim 37.